

Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds

G. Bedi* and J. Redman

Department of Psychology, Monash University, Melbourne, Australia

Background. Although there have been several reports linking ecstasy use with lowered cognitive function, much previous research suffers from substantial methodological limitations. The present study aimed to examine associations between ecstasy use and higher-level cognitive functions, using a larger sample size than most previous research and better controlling for a range of potential confounds.

Method. A cross-sectional cohort design assessed 45 currently abstinent ecstasy polydrug users (EP), 48 cannabis polydrug users (CP) and 40 legal drug users (LD). Standardized neuropsychological tests were used to measure attention, verbal, visual and working memory and executive function. Prospective memory function was also assessed.

Results. It was not possible to discriminate between groups on the basis of the cognitive functions assessed. Regression analyses showed an inverse association between lifetime dose of ecstasy and verbal memory performance. A combination of drug-use variables, including measures of ecstasy use, contributed to prediction of attention/working memory. However, individual associations were small, explaining 1–6% of variance in cognitive scores.

Conclusions. Although the results suggest that heavy use of ecstasy is associated with some lowering of higher-level cognitive functions, they do not indicate a clinical picture of substantial cognitive dysfunction.

Received 11 December 2006; Revised 8 November 2007; Accepted 18 December 2007

Key words: Cannabis, cognition, ecstasy, memory, polydrug.

Introduction

±3,4-Methylenedioxymethamphetamine (MDMA; 'ecstasy') damages serotonin neurones in animals (Ricaurte *et al.* 1988), as demonstrated with neurochemical (Battaglia *et al.* 1988) and immunohistochemical (Wilson *et al.* 1989b) techniques. Lowered cerebrospinal fluid levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA; McCann *et al.* 1994) and blunted neuroendocrine response to pharmacological challenge (McCann *et al.* 1999) indicate lowered serotonergic function in some human ecstasy users. The extent to which putative alterations to the serotonin system cause behavioural impairments in ecstasy users continues to be debated (Cole *et al.* 2002; Hoshi *et al.* 2007).

One behavioural domain previously investigated is cognition. Thought to be partially mediated by serotonergic function, a range of evidence suggests that

ecstasy users have lower cognitive function than non-users (e.g. Bolla *et al.* 1998; Fox *et al.* 2002; Kalechstein *et al.* 2007). Findings, however, are inconsistent. Some studies report comparative deficits in verbal but not visual memory (Bhattachary & Powell, 2001), others in the visual but not the verbal domain (Back-Madruga *et al.* 2003), whereas others suggest lowered executive function (Halpern *et al.* 2004). Conversely, some data indicate that ecstasy users have lowered memory but not executive function (Gouzoulis-Mayfrank *et al.* 2003), while others report an effect of drugs other than ecstasy (Croft *et al.* 2001; Hoshi *et al.* 2007). In a notable exception, comparatively light ecstasy users demonstrated lowered function on a broad range of tests (Yip & Lee, 2005). The results of a recent meta-analysis indicate that ecstasy use is associated with impairments in a variety of domains (Kalechstein *et al.* 2007). These analyses did not, however, include more recent studies reporting few ecstasy-specific impairments (e.g. Lamers *et al.* 2006; Roiser *et al.* 2007). Moreover, even criteria used in the 'stringent' meta-analyses did not take account of many potential confounds associated with this field (Cole *et al.* 2002), discussed later.

* Address for correspondence: G. Bedi, D.Psych., Human Behavioral Pharmacology Laboratory, Department of Psychiatry, University of Chicago, 5841 S. Maryland Ave., MC 3077, Chicago, IL 60637, USA.

(Email: gbedi@bsd.uchicago.edu)

The results of longitudinal investigations are also inconsistent. Whereas Zakzanis & Campbell (2006) found that continuing ecstasy users declined and ex-users improved in memory over time, Gouzoulis-Mayfrank *et al.* (2005) reported no change over 18 months. Another longitudinal study showed lowered verbal memory in ex-users but not current ecstasy users at baseline (Thomasius *et al.* 2003) and a relative absence of functional changes over 2 years (Thomasius *et al.* 2006). In the only prospective study to date, incidental ecstasy use had no effect on cognitive function in one subset (Jager *et al.* 2007); however, in another subset, beginning ecstasy users failed to demonstrate retest improvements in verbal memory shown by the naïve group (Schilt *et al.* 2007).

These inconsistencies are probably related partially to different methodologies, with existing evidence subject to a range of substantial methodological limitations (Cole *et al.* 2002), including:

- (1) *Self-report drug histories.* Use of self-report ecstasy dose measures in a population with possible memory impairments is problematic (Bedi & Redman, 2006). Estimation methods using contextual cues (e.g. life events) to improve recall may produce better estimations (Bedi & Redman, 2006), but few studies have used such methods.
- (2) *Compliance with drug-free periods.* Many studies have not biochemically confirmed drug-free status at assessment (e.g. Croft *et al.* 2001).
- (3) *Demographics.* Some studies have not controlled for effects of gender, age and education (e.g. Fox *et al.* 2002), which may impact on cognition (Lezak *et al.* 2004).
- (4) *Family of origin.* The presence of mental illness (Ozgun & Munir, 2005) and alcoholism/substance abuse (Giancola & Tarter, 1999) in the family of origin may affect cognitive development. Very few studies have included control for family of origin variables (for an exception, see Halpern *et al.* 2004).
- (5) *Pre-morbid intelligence.* Although most previous studies have included control for estimated pre-morbid intelligence, some have not (e.g. Zakzanis & Campbell, 2006).
- (6) *Mood.* Most studies have not controlled for possible effects of lowered mood at assessment (Lezak *et al.* 2004).
- (7) *Lifestyle.* Although some designs have included control for effects of sleep deprivation and erratic nutrition associated with the rave subculture (e.g. Halpern *et al.* 2004), many have not (e.g. Fox *et al.* 2002).
- (8) *Other drugs.* Most ecstasy users consume other drugs in addition to ecstasy, many of which may be associated with lowered cognition (Halpern *et al.*

2004). Although recent studies have used polydrug comparison groups or statistical methods to control for other drug use, many earlier studies did not (e.g. Parrott *et al.* 1998). Recruitment of rare 'pure' ecstasy-using samples may also avoid interpretative difficulties (Halpern *et al.* 2004). However, preclinical evidence of interactive effects between MDMA and other drugs (e.g. Clemens *et al.* 2005) suggests that it is important to assess for ecstasy effects in the context of polydrug use. A recent study investigating the effects of ecstasy in polydrug users with a well-matched polydrug, non-ecstasy comparison found deficits associated with cannabis rather than ecstasy use (Lamers *et al.* 2006). Another recent investigation found no substantive differences in cognition between current ecstasy users and either polydrug or drug-naïve controls (Roiser *et al.* 2007). However, earlier studies found ecstasy users to have lowered function compared to both polydrug and drug-naïve controls (e.g. Gouzoulis-Mayfrank *et al.* 2000), suggesting that further investigation is required.

There is substantial variability in the extent to which previous research has addressed the issues outlined above. Some early studies addressed few or none of the eight methodological issues (e.g. Parrott *et al.* 1998), whereas others have included some control for most (e.g. Halpern *et al.* 2004). To our knowledge, no previous study reports attempting to address all of these issues.

The present study aimed to assess cognition in relation to ecstasy use, while better controlling for the methodological issues outlined above. Because the majority of previous studies used small sample sizes, we also recruited larger samples to increase statistical power and reduce sampling bias. In line with earlier research, we focused on higher-level functions such as memory and executive function.

We hypothesized that, even after control for potential confounds, ecstasy users would demonstrate lower cognition than non-users (both other polydrug users and legal drug users). It was further anticipated that there would be a dose-dependent relationship between the extent of ecstasy use and the functions assessed.

Method

Participants

Participants ($n=133$) were 45 ecstasy polydrug users (EP; use of ecstasy and cannabis ≥ 10 times), 48 cannabis polydrug users (CP; use of cannabis ≥ 10 times, variable other drug use), and 40 legal drug (e.g. alcohol) users (LD; use of cannabis ≤ 5 times, any

other illicit drug ≤ 1 time). All participants were over 18 years. No CP or LD participant reported ecstasy use. We recruited participants using 'snowball' sampling (Parrott *et al.* 1998) and advertisements in local universities, shops, the 'street' press, and on websites (e.g. www.pillreports.com).

Full exclusion criteria have been presented elsewhere (Bedi & Redman, *in press*). In summary, participants were excluded based on:

- past/current medical problems likely to impact on cognition.
- previous/current psychiatric diagnosis/treatment except mood disorders.
- benzodiazepine use $\geq$ weekly for ≥ 6 months; intravenous opiate use; current use of > 3 units of alcohol/day > 5 times/week, of cocaine > 1 time/month, or of opiates or amphetamines > 1 time/week; current substance dependence excluding ecstasy, cannabis or nicotine; positive urinalysis for any drug except cannabis (see Simon & Mattick, 2002); and a positive breathalyser reading.
- insufficient English fluency, as measured by the Wechsler Test of Adult Reading (WTAR) raw score < 25 .

Procedure

A cross-sectional cohort design was used, with CP controls included to allow assessment of whether any group differences were ecstasy specific (Morgan, 1999).

Participants attended two sessions after phone screening. In-person assessment was divided to minimize fatigue due to the 3- to 4-h protocol. In session 1, participants provided demographic and drug-use information and completed self-report memory measures and prospective memory tasks. In session 2, participants completed neuropsychological testing and anxiety and depression measures. Participants provided written informed consent and were reimbursed \$AUD40 according to procedures approved by Monash University human ethics committee.

Participants were asked to abstain from alcohol for 24 h, caffeine for 2 h, and ecstasy and all recreational drugs other than cannabis for 10 days prior to attendance. They were requested to abstain from cannabis for 24 h (Fox *et al.* 2001). Although heavy cannabis use may affect cognition for 7 days (Pope *et al.* 2001), possible subacute effects were weighed against withdrawal effects if longer abstinence was required (Pope & Yurgelun-Todd, 2004). We balanced these concerns by requesting a cannabis-free period of 24 h and controlling statistically for recent cannabis-use effects where necessary. Because nicotine withdrawal reduces cognitive function (Parrott *et al.* 1996), participants smoked cigarettes as usual.

In 21 cases, data from participants reporting failure to fully comply with requirements were included, where the abstinence period approximated that requested and the amount of substance used was small (see Croft *et al.* 2001). Minimum abstinence periods were: alcohol 16 h; ecstasy 9 days; hallucinogens 5 days; benzodiazepines 5 days; and cannabis 20 h. 'Pure sample' analyses excluding these cases were conducted where necessary.

Participants had no major change to their sleeping routine for 4 days and sessions occurred between 13:00 and 20:00 hours to minimize circadian variations. Participants ate an amount they would normally consume for lunch to reduce possible low blood sugar effects.

Assessments were administered individually. Participants provided a breath sample using a Lion Alcometer SD-2 in both sessions (no positive reading was detected). Urine samples were collected in each session; however, resource restrictions limited the number analysed. A randomly selected subset ($n = 40$) of session 2 samples was subject to immunoassay screening for drugs of abuse (Dorevitch Pathology, Melbourne, Australia). One EP sample tested positive for opiates and one recorded a low creatinine level, indicating possible dilution (both datasets were excluded). Three EP and two CP samples tested positive to cannabis metabolites. Because metabolites can be detected for days after use, these datasets were not excluded (see Simon & Mattick, 2002).

Demographic and drug-use information

Demographic and drug-use information was collected with a structured interview (see Bedi & Redman, *in press*). Substance dependence was assessed using DSM-IV-based questions (APA, 1994). A Family of Origin Risk Index was developed for this study as a composite of the number of first-degree relatives diagnosed with psychiatric disorders, the number who used illegal drugs, and the number with alcohol-related problems. These variables were selected because family of origin mental illness and alcoholism/substance use may affect cognitive development (Giancola & Tarter, 1999; Ozgur & Munir, 2005). EP participants provided ecstasy-use information with an 'Ecstasy Use Timeline' (Bedi & Redman, 2006). Participants were asked about use of nicotine, alcohol, cannabis, stimulants, dissociatives, hallucinogens, opiates, inhalants, and tranquilizers.

Prospective memory tests

Two prospective memory tasks were embedded in session 1. The first, designated Reminder, was a modified version of the Rivermead Behavioural Memory Test Belonging subtest (Wilson *et al.* 1989a).

As the participant and researcher entered the room, the participant was asked to remind the researcher to lock the door at the end of the session. A reminder at the appropriate time scored one, whereas no reminder scored zero. The second prospective memory test, designated Crosses, was modified from the 2-min event-based task used by Hannon *et al.* (1995). The modified task used a self-report memory questionnaire as the distracter. While filling out this questionnaire, participants marked the bottom of each page with a cross. Scores reflected the number of pages correctly marked.

Neuropsychological battery

English language capacity (see Morgan, 1999)/estimated pre-morbid intelligence were measured using the WTAR (The Psychological Corporation, 2001). Verbal memory was assessed with the Rey Auditory Verbal Learning Test (RAVLT; Schmidt, 1996). Standard RAVLT variables included Immediate Recall, Delayed Recall, Learning (highest score in first five trials minus Trial 1), Short-Term Index (sum of Trials 1, 2 and List B) and Recognition (List A targets correctly identified; see Schmidt, 1996). Recognition – Correct Negatives (distractors correctly identified; Spreen & Strauss, 1998) was also included to assess impulsive responding. Executive function was measured with the six subscores and overall profile score of the Behavioural Assessment of the Dysexecutive Syndrome (BADS; Wilson *et al.* 1996). Verbal association fluency, also associated with frontal lobe function, was assessed using the Controlled Oral Word Association test (COWA; Lezak *et al.* 2004). COWA variables included total FAS and Animal scores and errors (Spreen & Strauss, 1998). Visual memory was measured with the Copy, Immediate and Delayed Recall and Recognition trials of the Rey Complex Figure Test (RCFT; Meyers & Meyers, 1995). Forward and Backward trials of the Digit Span subtest of the Wechsler Adult Intelligence Scale – Third Edition (WAIS-III; Wechsler, 1997) were used. Digit Span Forwards measures short-term auditory memory span and Digit Span Backwards tests verbal working memory (Lezak *et al.* 2004).

Mood

Depressive symptomatology was rated using the Center for Epidemiologic Studies Depression Scale – Revised (CESD-R; Eaton *et al.* 2004). Anxiety symptomatology was assessed with the Beck Anxiety Inventory (BAI; Beck & Steer, 1993).

Three self-report memory questionnaires and a memory monitoring exercise were also completed. These data are reported elsewhere (Bedi & Redman, *in press*).

Statistical analyses

One-way analyses of variance (ANOVAs), independent *t* tests and χ^2 tests assessed for group differences in demographics, mood and drug use. Following ANOVA, *post-hoc* comparisons with Bonferroni corrections were used as follows: (1) EP *v.* CP; (2) where EP = CP, EP + CP *v.* LD; and (3) where EP $\neq$ CP, EP *v.* CP + LD. This approach determined whether differences were specific to ecstasy, or were associated with drug use in general. Because *t* tests and ANOVAs are relatively robust to violations of the assumption of normality (Gravetter & Wallnau, 2004), we retained non-normal data.

Discriminant Function Analysis (DFA) assessed whether individual cognitive variables and/or patterns of variables differentiated groups. The analysis was carried out in four parts: the first examined verbal memory, the second visual memory, the third executive function and the fourth variables measuring attention, verbal working memory and short-term prospective memory. Within the DFAs, the discriminative value of individual variables was assessed with ANOVAs. For the dichotomous cognitive variable (the Reminder prospective memory test), group differences were examined using a χ^2 test.

Relationships between drug-use variables and cognitive outcomes were examined in the whole sample. Drug-use variables included total lifetime ecstasy dose, average and largest ecstasy dose, ecstasy use in the preceding month, total lifetime cannabis dose, cannabis use in the preceding month, total lifetime dose of amphetamines, cocaine, LSD and alcohol, and polydrug use (number of recreational drugs ever used).

Principal Components Analysis (PCA) reduced the number of dependent variables (Tabachnick & Fidell, 2001) for dose-response analyses (the full set of cognitive variables was used in earlier DFAs). Hierarchical multiple regression analyses separated contributions of demographic variables/pre-morbid intelligence, mood and drug use to variability on the cognitive factor scores yielded. To reduce the number of independent variables, backward multiple regressions were used to identify the demographic/pre-morbid intelligence variables most likely to contribute to prediction of each factor, the most relevant mood variables and the most relevant drug-use variables. We entered variables retained in preliminary backward regressions into final models, with pre-morbid intelligence/demographics entered first, mood variables second, and drug-use measures last. Examination of the drug-use variable correlation matrix indicated no threat to analyses due to multicollinearity, using the $r < 0.9$ threshold (Tabachnick &

Table 1. Demographic features of participants

	Ecstasy polydrug (<i>n</i> = 45)	Cannabis polydrug (<i>n</i> = 48)	Legal drug (<i>n</i> = 40)	Group differences χ^2 (df = 2)		
Sex, female, <i>n</i> (%)	21 (47)	22 (46)	19 (48)	0.02		
Birth in English-speaking country, <i>n</i> (%)	38 (84)	40 (83)	27 (68)	4.53		
Student, <i>n</i> (%)	30 (67)	37 (77)	32 (80)	2.26		
University educated, <i>n</i> (%)	13 (29)	7 (15)	17 (43)	8.51*		
Diagnosis of affective disorder, <i>n</i> (%)	13 (29)	7 (15)	2 (5)	8.96*		
					Overall differences <i>F</i> (df)	EP <i>v.</i> CP <i>t</i> (df) EP + CP <i>v.</i> LD <i>t</i> (df)
Depression – CESD-R, mean (s.d.)	12.2 (9.7)	14.0 (9.0)	9.4 (6.3)	3.38* (2, 130)	0.94 (91)	2.39* (131)
Anxiety – BAI, mean (s.d.)	8.6 (7.9)	8.1 (6.0)	4.7 (4.0)	4.99* (2, 130)	0.32 (91)	3.89* (121.49)
Index of family risk, mean (s.d.)	2.1 ^a (1.8)	2.3 ^b (1.7)	0.6 ^c (1.0)	13.93* (2, 117)	0.27 (82)	6.52* (108.62)
Illegal drug use (first-degree relatives), mean (s.d.)	1.6 ^d (1.3)	1.6 ^b (1.3)	0.4 ^c (0.7)	14.92* (2, 119)	0.17 (84)	7.03* (115.60)
Alcohol abuse (first-degree relatives), mean (s.d.)	0.2 ^a (0.6)	0.2 ^b (0.5)	0.1 ^c (0.3)	0.81 (2, 117)	–	–
Psychiatric disorders (first-degree relatives), mean (s.d.)	0.3 (0.6)	0.4 (0.8)	0.1 (0.3)	2.17 (2, 130)	–	–
Age, years, mean (s.d.)	22.8 (3.0)	21.7 (3.5)	23.1 (3.7)	2.13 (2, 130)	–	–
WTAR raw score/standard score ^e , mean (s.d.)	38.6/109 (6.1)	38.5/109 (5.1)	37.3/107 (5.7)	0.79 (2, 130)	–	–

EP, Ecstasy polydrug users; CP, cannabis polydrug users; LD, legal drug users; CESD-R, Center for Epidemiologic Studies Depression Scale – Revised; BAI, Beck Anxiety Inventory; WTAR, Wechsler Test of Adult Reading; df, degrees of freedom; s.d., standard deviation.

^a *n* = 37 due to missing data.

^b *n* = 47 due to missing data.

^c *n* = 36 due to missing data.

^d *n* = 39 due to missing data.

^e Standard scores were calculated from mean raw scores using US norms and are presented in Table 2 to facilitate interpretation. Raw scores were used in subsequent analyses because Australian norms are not available for this test.

* *p* < 0.05, with Bonferroni corrections where necessary.

Fidell, 2001). Examination of tolerance statistics also indicated an absence of multicollinearity in regressions. Analyses were performed using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA).

Results

Demographics

Table 1 shows that groups did not differ in age, pre-morbid intelligence, gender, birth in an English-speaking country, or student status. There was a non-significant trend towards the LD group having lower rates of birth in an English-speaking country than EP and CP groups [$\chi^2(2) = 4.53$, *p* = 0.10]. Groups differed in university degree completion, with LD and EP

participants more likely to have done so than CP users. There were differences in affective disorder diagnoses, with EP users having the highest rates and LD users the lowest. The combined polydrug group endorsed more depression and anxiety symptoms, and had more familial risk (secondary to higher rates of familial illegal drug use), than LD controls.

Drug use

As presented in Table 2, groups did not differ in alcohol use, but the combined polydrug group had smoked more cigarettes than LD controls. There were no significant differences between EP and CP groups in nitrous oxide, cocaine or ketamine use. Ecstasy users had higher lifetime use of amphetamines, ‘magic’

Table 2. *Patterns of drug use*

Lifetime dose	Ecstasy polydrug (<i>n</i> = 45) Mean (S.D.)	Cannabis polydrug (<i>n</i> = 48) Mean (S.D.)	Legal drug (<i>n</i> = 40) Mean (S.D.)	Overall differences <i>F</i> (df)	EP <i>v.</i> CP <i>t</i> (df)	EP + CP <i>v.</i> LD <i>t</i> (df)
Alcohol (standard drinks)	4033.8 (5746.8)	3175.0 (3249.4)	1990.8 (3865.1)	2.87 (2, 130)	–	–
Nicotine (cigarettes)	12266.2 (20510.7)	8845.4 (20005.9)	1204.0 (3637.1)	5.52* (2, 130)	1.03 (91)	4.60* (102.02)
Amphetamines (g)	23.5 (68.4)	0.3 (1.1)	0 (0)	–	2.68* (44.02)	–
Nitrous oxide (bulbs)	215.3 ^a (619.6)	80.2 ^b (499.0)	0 (0)	–	1.72 (63.95)	–
LSD (tabs)	76.9 (328.4)	22.1 (146.7)	0 (0)	–	1.50 (91)	–
'Magic' mushrooms (occasions of use)	14.7 (41.7)	2.2 (10.8)	0 (0)	–	2.52* (47.32)	–
Cocaine (g)	4.0 (16.3)	1.6 (10.6)	0 (0)	–	1.27 (91)	–
Amyl nitrate (occasions of use)	1.7 (4.7)	0.5 (2.7)	0 (0)	–	2.18* (91)	–
Benzodiazepines (tablets)	8.3 ^a (18.0)	3.0 ^d (20.1)	0 (0)	–	2.25* (74)	–
Ketamine (g)	0.7 ^c (3.0)	0 (0)	0 (0)	–	1.74 (42.01)	–
No. of recreational drugs ever used	12.2 (4.4)	5.2 (3.2)	1.9 (0.8)	–	9.00* (76.3)	–
Cannabis (g)	355.6 (616.9)	360.4 (634.2)	0.1 (0.3)	–	0.01 (91)	–
Time since last use cannabis (days)	91.8 (169.7)	267.5 (585.0)	2058.3 ^e (2001.5)	–	2.09* (55.92)	–
	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)			
Regular cannabis use in preceding month ^f	4 (9)	5 (10)	0 (0)	–	Fisher's test (<i>p</i> = 1.00)	–
Use of cannabis in preceding month ^g	30 (67)	29 (60)	1 (3)	–	$\chi^2(1) = 0.39$	–
	Mean (S.D.)	Range				
Age of first ecstasy use ^h	18.6 (2.2)	15–27				
Lifetime occasions of ecstasy use ^h	77.8 (89.1)	13–483				
Lifetime total ecstasy dose (pills) ^h	170.6 (362.8)	13.5–2407				
Average ecstasy dose/occasion (pills) ^a	1.7 (0.9)	0.5–5				
Largest ecstasy dose/occasion (pills) ^h	4.5 (3.7)	1–21				
Time since last ecstasy use (days) ^{i,j}	79.2 (108.5)	10–425				

EP, Ecstasy polydrug users; CP, cannabis polydrug users; LD, legal drug users; df, degrees of freedom; S.D., standard deviation.

^a *n* = 44 due to missing data.

^b *n* = 46 due to missing data.

^c *n* = 46 due to missing data.

^d *n* = 47 due to missing data.

^e *n* = 10.

^f Defined as use four or more times per week.

^g Last reported use of cannabis within 30 days of participation.

^h In EP group, *n* = 45.

ⁱ *n* = 44 due to missing data.

^j Prior to neuropsychological assessment session.

Table 3. Cognitive function in EP, CP and LD users

	EP (<i>n</i> = 45)	CP (<i>n</i> = 48)	LD (<i>n</i> = 40)
RAVLT Short-Term Index	24.2 (5.2)	24.8 (5.8)	24.4 (4.3)
RAVLT Learning	5.7 (1.8)	6.4 (1.7)	6.0 (1.8)
RAVLT Immediate Recall	11.7 (2.2)	12.5 (2.3)	11.8 ^a (1.9)
RAVLT Delayed Recall	11.3 (3.0)	12.0 (2.6)	11.4 ^a (2.1)
RAVLT Recognition	13.6 (1.4)	14.1 (1.3)	13.7 ^a (1.4)
RAVLT Recognition – Correct Negatives	33.9 (1.9)	34.3 (1.1)	34.3 ^a (1.6)
RCFT Copy	31.5 (2.8)	32.2 (2.7)	31.3 (3.6)
RCFT Immediate Recall	22.0 (4.1)	23.0 (4.4)	21.9 (5.3)
RCFT Delayed Recall	20.7 (3.9)	22.5 (4.3)	20.9 (5.7)
RCFT Recognition	21.0 (1.7)	21.3 (1.5)	21.4 (1.7)
BADS Rule Shift	3.6 (0.8)	3.6 (0.5)	3.4 (0.9)
BADS Action Program	3.7 ^d (0.6)	3.9 ^c (0.3)	3.7 (0.6)
BADS Key Search	2.8 (1.1)	2.8 ^c (1.2)	3.0 (1.0)
BADS Temporal Judgement	1.4 ^d (0.7)	1.6 (0.6)	1.5 (0.7)
BADS Zoo Map	3.1 ^b (1.1)	2.6 (1.2)	2.9 ^e (1.0)
BADS Six Elements	3.8 (0.5)	3.8 (0.6)	3.7 (0.6)
BADS Profile Score	18.4 (2.4)	18.3 (2.2)	18.2 (2.5)
COWA FAS Total	41.3 (9.8)	41.9 (9.9)	41.6 (11.0)
COWA Animals	23.7 (4.9)	23.3 (5.3)	23.9 (5.5)
COWA Errors	2.6 (1.9)	2.3 (1.9)	2.3 (1.7)
WAIS-III Digit Span Forwards	10.8 (2.6)	11.3 (2.3)	11.9 (2.4)
WAIS-III Digit Span Backwards	7.5 (2.8)	8.1 (2.2)	8.4 (2.6)
Crosses	25.8 (4.4)	25.4 (4.8)	27.6 ^e (2.7)
Reminder, <i>n</i> (correct) (%)	25 ^b (58)	22 ^c (47)	19 ^d (49)

EP, Ecstasy polydrug users; CP, cannabis polydrug users; LD, legal drug users; RAVLT, Rey Auditory Verbal Learning Test; RCFT, Rey Complex Figure Test; BADS, Behavioural Assessment of the Dysexecutive Syndrome; COWA, Controlled Oral Word Association; WAIS-III, Wechsler Adult Intelligence Scale – Third Edition.

Values are mean (S.D.), except 'Reminder'.

^a *n* = 39 due to missing data.

^b *n* = 43 due to missing data, valid percentages are presented (where relevant).

^c *n* = 47 due to missing data, valid percentages are presented (where relevant).

^d *n* = 44 due to missing data, valid percentages are presented (where relevant).

^e *n* = 38 due to missing data.

mushrooms, amyl nitrate and benzodiazepines, and reported use of more recreational drugs than CP users. The two polydrug groups were well matched on lifetime cannabis dose and cannabis use in the month preceding assessment.

Cognitive function – group analyses

Table 3 shows mean neuropsychological scores. None of the DFAs yielded functions that differentiated EP from CP or LD users. Examination of the discriminative capacity of individual variables revealed only one variable that differentiated groups [Crosses; $F(2, 128) = 3.22$, $p = 0.04$]. Although this finding would have emerged if 23 univariate analyses were conducted without Bonferroni correction, this is

likely to represent a Type 1 error given the number of analyses. *Post-hoc* comparisons show that, although polydrug users scored lower on this measure than LD controls, there was no difference between EP and CP users. The χ^2 test indicated no relationship between group membership and performance on the Reminder test.

Because there was a non-significant trend towards LD users having lower rates of birth in an English-speaking country, and this trend might have contributed to negative results, all group analyses were repeated using only participants born in an English-speaking country ($n = 105$). These analyses also revealed no differences. Because patterns of cognitive function did not discriminate groups, and all other potential confounds would favour LD

participants over EP and CP groups, we did not assess for possible impacts of other demographic/mood covariates, nor did we undertake 'pure sample' analyses excluding participants who did not fully comply with abstinence requirements.

Data reduction

After removal of nine unfactorable variables, PCA using varimax rotation resulted in the extraction of five factors. As shown in Table 4, four of the five factors were readily interpretable, with the first representing verbal memory, the second visual memory, the third verbal fluency and the fourth attention/working memory. The fifth factor was not interpretable and was excluded from further analyses. Factor scores were obtained using the regression method (Tabachnick & Fidell, 2001).

Relationships between drug-use variables and cognitive function

Preliminary regression analyses indicated that for each of the PCA-extracted cognitive factors, one or more of the demographic and drug-use variables contributed to the regression equation. Neither mood variable was retained in any of the preliminary analyses. Hierarchical regressions, therefore, included only two steps, with relevant demographic variables entered first and drug-use variables second.

Drug-use variables did not contribute to prediction of visual memory or verbal fluency, once demographic variability was accounted for. As shown in Table 5, ecstasy lifetime dose predicted verbal memory, with higher use associated with lower verbal memory performance ($sr = -0.20$, $sr^2 = 0.04$). A combination of drug-use variables predicted attention/working memory. Weak negative semi-partial correlations were found between average dose of ecstasy ($sr = -0.24$, $sr^2 = 0.06$) and lifetime LSD dose ($sr = -0.10$, $sr^2 = 0.01$) and attention/working memory scores. A weak positive correlation was found between this cognitive measure and lifetime cocaine dose ($sr = 0.14$, $sr^2 = 0.02$) and use of ecstasy in the month prior to participation ($sr = 0.20$, $sr^2 = 0.04$).

To investigate possible impacts of failure to fully comply with drug-related requirements, follow-up regression analyses were conducted excluding these 21 cases ($n = 112$). These analyses revealed a similar pattern of relationships between cognitive factor scores and drug-use variables. Higher lifetime dose of ecstasy was weakly associated with lower verbal memory performance and no drug-use variable contributed to prediction of visual memory or verbal fluency, once demographic factors were accounted for. The same drug-use variables predicted

Table 4. Rotated component matrix: principal components analysis

	Factor				
	1	2	3	4	5
RAVLT delayed recall	0.86				
RAVLT immediate recall	0.86				
RAVLT recognition	0.63				
RAVLT recognition – correct negatives	0.63				
RAVLT short-term index	0.61				
RCFT immediate recall		0.91			
RCFT delayed recall		0.88			
RCFT copy		0.75			
COWA FAS total			0.73		
COWA animals total			0.67		
COWA errors total	–0.48		0.56		
Digit Span Forwards				0.84	
Digit Span Backwards				0.84	
RCFT recognition					0.73
Crosses					–0.65
% of variance	24.30	14.68	11.40	7.48	6.99

RAVLT, Rey Auditory Verbal Learning Test; RCFT, Rey Complex Figure Test; COWA, Controlled Oral Word Association test.

Table 5. Demographic and drug-use variables as predictors of verbal memory and attention/working memory

Model	R	R ²	Adjusted R ²	p	Change R ²	p
Verbal Memory Factor Score ($n = 116$)						
1 ^a	0.34	0.12	0.09	0.00	0.12	0.00
2 ^b	0.39	0.15	0.12	0.00	0.03	0.04
Attention/Working Memory Factor Score ($n = 124$)						
1 ^c	0.39	0.15	0.13	0.00	0.15	0.00
2 ^d	0.48	0.23	0.19	0.00	0.08	0.02

^a Predictors: Sex, Index of Family Risk, Completed University degree.

^b Predictors: Sex, Index of Family Risk, Completed University degree, Lifetime total dose of ecstasy.

^c Predictors: Birth in English-speaking country, WTAR raw score, Full-time employed.

^d Predictors: Birth in English-speaking country, WTAR raw score, Full-time employed, Average dose of ecstasy, Use of ecstasy in past month, Lifetime total dose of LSD, Lifetime total dose of cocaine.

attention/working memory scores, with relationships between individual variables in the same direction and of similar magnitude to those reported above. The only difference apparent in follow-up analyses was the

addition of a very small relationship between amphetamine use and verbal memory, with higher lifetime dose associated with better function ($sr=0.12$, $sr^2=0.01$).

Discussion

The hypothesis that ecstasy users would display lower cognition than non-users was not supported. There was some support for dose-response relationships, with ecstasy variables predicting verbal memory and attention/working memory. However, individual relationships were small.

Mean group performance on the RAVLT (Schmidt, 1996), COWA (Ruff *et al.* 1996), BADS (Wilson *et al.* 1996) and Digit Span (Wechsler, 1997) fell within clinically normal ranges. Some mean RCFT scores were below average but not indicative of clinically significant impairment (Meyers & Meyers, 1995).

There are a number of possible reasons for the absence of group-level ecstasy effects. Assessments were primarily clinical neuropsychological tests, which may not have been sufficiently sensitive to detect subtle alterations. Research using acute tryptophan depletion has, however, found a version of the RAVLT and a set-shifting task similar to the BADS Rule Shift Cards subtest to be sensitive to experimentally lowered 5-HT (Park *et al.* 1994; Riedel *et al.* 1999), supporting the capacity of this protocol to detect variations arising from altered serotonergic function. However, it remains possible that ecstasy use was associated with subtle neuronal dysfunction without detectable cognitive consequences.

An alternative explanation is that MDMA dosages were not sufficient to produce serotonergic damage and cognitive dysfunction. Recently manufactured ecstasy may not be as potent as earlier tablets, which could explain the difference between the present and some earlier findings. However, such a difference would not explain other recent findings of ecstasy-specific cognitive dysfunction (e.g. Yip & Lee, 2005). It is also possible that ecstasy in Australia may be less potent than that available in other countries. However, given that the majority of Australian MDMA-containing pills originate in Western Europe (Australian Crime Commission, 2005), substantial content differences between Australia and Europe are unlikely. Australian ecstasy users do appear to use less ecstasy per session than those in the UK, possibly lowering the potential for neurotoxicity. British samples typically use more than three tablets (Sumnall *et al.* 2004), whereas Australians use one tablet per occasion (Ward *et al.* 2006). Ecstasy-use patterns in the current sample are similar to those reported in other Australian samples (e.g. Stafford *et al.* 2004; Ward *et al.*

2006), suggesting that this sample is broadly representative.

Other samples with similar or lower levels of use have previously been reported to have reduced cognitive function (e.g. Ward *et al.* 2006), indicating that lower doses alone are not entirely responsible for the difference between current and some earlier findings. It is also likely that control for a broader range of confounds contributed to the absence of group-level findings in this study. This is supported by recent studies, using better methodological controls than earlier research, that have also reported limited ecstasy-specific effects (e.g. Lamers *et al.* 2006; Hoshi *et al.* 2007; Roiser *et al.* 2007).

In addition to the absence of group ecstasy effects, there was no group cannabis effect. Lowered cognition in heavy cannabis users is likely to be due to subacute effects that 'wash-out' over around 1 month (Pope *et al.* 2001). Therefore, heavy use in the past month is likely to be the most relevant cannabis-use dimension impacting cognition. Very few EP or CP users in this study reported heavy cannabis use prior to participation. Because few previous ecstasy studies have reported this cannabis-use dimension, it is possible that some earlier positive results were due to recent cannabis use rather than chronic effects (see Hoshi *et al.* 2007).

Although there were no ecstasy-specific group effects, inverse associations were found between ecstasy-use measures and verbal memory and attention/working memory. The association between ecstasy and verbal memory is among the more consistent findings in previous research, and verbal memory is the only cognitive dimension where prospective data have indicated that ecstasy may have an effect (Schilt *et al.* 2007). However, the present pattern of results does not present a compelling picture of substantial cognitive dysfunction, with heavy ecstasy use only weakly associated with lowered cognition. It is possible that subtle effects in young adults may become more pronounced with ageing, with ecstasy users perhaps at greater risk for earlier/more severe cognitive declines (Morgan, 2000). Indeed, it is possible that the present absence of group ecstasy effects could be due to the relatively young sample, who may have had intact compensating mechanisms. Despite being a potential public health issue in the future, however, longer-term effects of ecstasy use remain unknown.

Although this study aimed to better address methodological issues than previous research, limitations remain. The absence of pre-morbid data and non-experimental design limits possible causal interpretation. Although we attempted to control for non-ecstasy drug use, the possibility of other drug

effects cannot be entirely excluded in any polydrug sample. Despite the noted importance of verification of drug-free status, we were only able to perform urine assays on a subset of samples. Participants were not, however, informed of this, which may have encouraged compliance. A further limitation involves the focus on memory and executive function, meaning that differences in cognitive dimensions not assessed may have gone undetected. However, test selection was based on previous evidence regarding functions most likely to be affected.

Inconsistencies in previous findings suggest that there may be substantial individual variability in vulnerability to ecstasy-related sequelae, differences that might explain the divergent results in the overall body of literature. Future research should focus on identification of ecstasy users at particular risk of negative effects. Although heavier use seems to increase risk, it has yet to be established whether individual characteristics also confer heightened vulnerability. There is preliminary evidence that acute and possibly chronic effects of ecstasy might differ based on sex (see Bolla *et al.* 1998; Allott & Redman, 2007). Another possibility is that genetic predispositions interact with use of ecstasy, making some users more vulnerable than others. Preliminary evidence examining interactions between genotype for a 5-HT transporter polymorphism and ecstasy use in terms of cognition has been contradictory, with one study reporting an interaction (Roiser *et al.* 2006) but another finding no such interactive effect (Reneman *et al.* 2006). It is also possible that early-onset ecstasy use, particularly occurring during the developmentally sensitive period of adolescence, may increase negative impacts (Jacobsen *et al.* 2004); however, this has yet to be assessed. Similarly, no previous research has examined possible differential effects of ecstasy based on pre-morbid cognitive levels.

In the absence of clear evidence about particular groups at risk, public health messages should convey potential dangers associated with ecstasy in a balanced and credible manner. At higher doses, ecstasy use seems to be weakly associated with reduced function in some cognitive domains. Although such effects seem to be subclinical in young adults, they may be associated with adverse consequences in the longer term.

Acknowledgements

We thank Kim Ng, John H. Halpern, Kelly Allott, Leila Greenfield, Nicholas Van Dam and participants. This project was funded by Monash University, Department of Psychology. G.B. was funded by an Australian Postgraduate Award.

Declaration of Interest

None.

References

- Allott K, Redman J (2007). Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)? *Neuroscience and Biobehavioral Reviews* **31**, 327–347.
- APA (1994). *Diagnostic and Statistical Manual of Mental Disorders*, 4th edn. American Psychiatric Press: Washington, DC.
- Australian Crime Commission (2005). *Illicit Drug Data Report 2003–2004*. Australian Crime Commission: Canberra, Australia.
- Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE (2003). Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. *Clinical Neuropsychologist* **17**, 446–459.
- Battaglia G, Yeh SY, De Souza EB (1988). MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. *Pharmacology, Biochemistry and Behavior* **29**, 269–274.
- Beck AT, Steer RA (1993). *Beck Anxiety Inventory Manual*. The Psychological Corporation: San Antonio, TX.
- Bedi G, Redman J (2006). Self-reported ecstasy use: the impact of assessment method on dosage estimates in recreational users. *Journal of Psychopharmacology* **20**, 432–436.
- Bedi G, Redman J (in press). Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean? *Journal of Psychopharmacology*.
- Bhattachary S, Powell JH (2001). Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. *Psychological Medicine* **31**, 647–658.
- Bolla KI, McCann UD, Ricaurte GA (1998). Memory impairment in abstinent MDMA ('Ecstasy') users. *Neurology* **51**, 1532–1537.
- Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS (2005). MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. *Neuropharmacology* **49**, 195–207.
- Cole JC, Sumnall HR, Grob CS (2002). Sorted: ecstasy facts and fiction. *Psychologist* **15**, 464–467.
- Croft RJ, Mackay AJ, Mills ATD, Gruzeliier JGH (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. *Psychopharmacology* **153**, 373–379.
- Eaton WW, Smith C, Ybarra M, Muntaner C, Tien A (2004). Center for Epidemiologic Studies Depression Scale: review and revision (CESD and CESD-R). In *The Use of Psychological Testing for Treatment Planning and Outcomes Assessment: Vol. 3: Instruments for Adults* (ed. M. E. Maruish), pp. 363–377. Lawrence Erlbaum Associates: Mahwah, NJ.

- Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ (2002). Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. *Psychopharmacology* **162**, 203–214.
- Fox HC, Toplis AS, Turner JJD, Parrott AC (2001). Auditory verbal learning in drug-free ecstasy polydrug users. *Human Psychopharmacology: Clinical and Experimental* **16**, 613–618.
- Giancola PR, Tarter RE (1999). Executive cognitive functioning and risk for substance abuse. *Psychological Science* **10**, 203–205.
- Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). *Journal of Neurology, Neurosurgery and Psychiatry* **68**, 719–725.
- Gouzoulis-Mayfrank E, Fischermann T, Rezk M, Thimm B, Hensen G, Daumann J (2005). Memory in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. *Drug and Alcohol Dependence* **78**, 317–323.
- Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003). Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **27**, 819–827.
- Gravetter FJ, Wallnau LB (2004). *Statistics for the Behavioral Sciences*, 6th edn. Wadsworth/Thomson Learning: Belmont, CA.
- Halpern JH, Pope Jr. HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D (2004). Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. *Drug and Alcohol Dependence* **75**, 135–147.
- Hannon R, Adams P, Harrington S, Fries-Dias C, Gipson MT (1995). Effects of brain injury and age on prospective memory self-rating and performance. *Rehabilitation Psychology* **40**, 289–298.
- Hoshi R, Mullins K, Boundy C, Brignell C, Piccini P, Curran HV (2007). Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naïve controls. *Psychopharmacology* **194**, 371–379.
- Jacobsen LK, Mendl W, Pugh KR, Skudlarski P, Krystal JH (2004). Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. *Psychopharmacology* **173**, 383–390.
- Jager G, de Win MM, Vervaeke HK, Schilt T, Kahn RS, van den Brink W, van Ree JM, Ramsey NF (2007). Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. *Psychopharmacology* **193**, 403–414.
- Lamers CTJ, Bechara A, Rizzo M, Ramaekers JG (2006). Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. *Journal of Psychopharmacology* **20**, 302–311.
- Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS (2004). *Neuropsychological Assessment*, 4th edn. Oxford University Press: New York.
- Kalechstein AD, De La Garza II R, Mahoney III JJ, Fantegrossi WE, Newton TF (2007). MDMA use and neurocognition: a meta-analytic review. *Psychopharmacology* **189**, 531–537.
- McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999). Altered neuroendocrine and behavioral m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. *Psychopharmacology* **147**, 56–65.
- McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994). Serotonin neurotoxicity after $\pm$ 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'): a controlled study in humans. *Neuropsychopharmacology* **10**, 129–138.
- Meyers JE, Meyers KR (1995). *Rey Complex Figure Test (RCFT) and Recognition Trial*. Psychological Assessment Resources: Odessa, FL.
- Morgan MJ (1999). Memory deficits associated with recreational use of 'ecstasy' (MDMA). *Psychopharmacology* **141**, 30–36.
- Morgan MJ (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. *Psychopharmacology* **152**, 230–248.
- Ozgun O, Munir K (2005). Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children. *Schizophrenia Research* **76**, 293–299.
- Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW, Cowen PJ (1994). Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. *Neuropharmacology* **33**, 575–588.
- Parrott AC, Garnham NJ, Wesnes K, Pincock C (1996). Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. *Human Psychopharmacology: Clinical and Experimental* **11**, 391–400.
- Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998). Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits. *Journal of Psychopharmacology* **12**, 79–83.
- Pope Jr. HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001). Neuropsychological performance in long-term cannabis users. *Archives of General Psychiatry* **58**, 909–915.
- Pope Jr. HG, Yurgelun-Todd D (2004). Residual cognitive effects of long-term cannabis use. In *Marijuana and Madness: Psychiatry and Neurobiology* (ed. D. Castle and R. Murray), pp. 198–210. Cambridge University Press: New York.
- Reneman L, Schilt T, De Win MML, Booij I, Schmand B, Van den Brink W, Bakker O (2006). Memory function and serotonin transporter gene polymorphism in ecstasy (MDMA) users. *Journal of Psychopharmacology* **20**, 389–399.
- Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW (1988). $\pm$ 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. *Journal of the American Medical Association* **260**, 51–55.

- Riedel WJ, Klaassen T, Deutz NEP, van Someren A, van Praag HM (1999). Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. *Psychopharmacology* **141**, 362–369.
- Roiser JP, Rogers RD, Cook LJ, Sahakian BJ (2006). The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls. *Psychopharmacology* **188**, 213–227.
- Roiser JP, Rogers RD, Sahakian BJ (2007). Neuropsychological function in ecstasy users: a study controlling for polydrug use. *Psychopharmacology* **189**, 505–516.
- Ruff RM, Light RH, Parker SB, Levin HS (1996). Benton Controlled Oral Word Association Test: reliability and updated norms. *Archives of Clinical Neuropsychology* **11**, 329–338.
- Schilt T, de Win MML, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B (2007). Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. *Archives of General Psychiatry* **64**, 728–736.
- Schmidt M (1996). *Rey Auditory Verbal Learning Test: A Handbook*. Western Psychological Services: Los Angeles, CA.
- Simon NG, Mattick RP (2002). The impact of regular ecstasy use on memory function. *Addiction* **97**, 1523–1529.
- Spreen O, Strauss E (1998). *A Compendium of Neuropsychological Tests: Administration, Norms and Commentary*. Oxford University Press: New York.
- Stafford J, Degenhardt L, Agalotis M, Chanteloup F, Fischer J, Matthews A, Newman J, Proudfoot P, Stooze M, Weekley J (2004). *Australian Trends in Ecstasy and Related Drug Markets 2004: Findings from the Party Drugs Initiative (PDI)*. National Drug and Alcohol Research Centre: Sydney, Australia.
- Sumnall HR, Tyler E, Wagstaff GF, Cole JC (2004). A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers. *Drug and Alcohol Dependence* **76**, 93–99.
- Tabachnick BG, Fidell LS (2001). *Using Multivariate Statistics*, 4th edn. Allyn and Bacon: Boston, MA.
- The Psychological Corporation (2001). *Wechsler Test of Adult Reading (WTAR) Manual*. The Psychological Corporation: San Antonio, TX.
- Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. *Psychopharmacology* **167**, 85–96.
- Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A (2006). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. *Journal of Psychopharmacology* **20**, 211–225.
- Ward J, Hall K, Haslam C (2006). Patterns of memory dysfunction in current and 2-year abstinent MDMA users. *Journal of Clinical and Experimental Neuropsychology* **28**, 306–324.
- Wechsler D (1997). *Wechsler Adult Intelligence Scale – Third Edition*. The Psychological Corporation: San Antonio, TX.
- Wilson BA, Alderman N, Burgess PW, Emslie H, Evans JJ (1996). *Behavioural Assessment of the Dysexecutive Syndrome*. Thames Valley Test Company: Bury St Edmonds, UK.
- Wilson BA, Cockburn J, Baddeley AD, Hiorns R (1989a). The development and validation of a test battery for detecting and monitoring everyday memory problems. *Journal of Clinical and Experimental Neuropsychology* **11**, 855–870.
- Wilson MA, Ricaurte GA, Molliver ME (1989b). Distinct morphological classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. *Neuroscience* **28**, 121–137.
- Yip J, Lee TMC (2005). Effects of ecstasy use on neuropsychological function: a study in Hong Kong. *Psychopharmacology* **179**, 620–628.
- Zakzanis KK, Campbell Z (2006). Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. *Neurology* **66**, 740–741.